Lokon Pharma

Focus: Lokon Pharma is a Sweden-based oncology immunotherapy company specializing in oncolytic virus platforms for cancer treatment. The company operates as a focused biotech with a lean pipeline in early-stage development.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 1w ago

Open Jobs

About Lokon Pharma

AI assessmentNot Hiring

No open roles listed right now. Follow Lokon Pharma to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

3 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

delolimogene mupadenorepvec

Malignant Melanoma

Phase 1/2

LOAd703

Pancreatic Adenocarcinoma

Phase 1/2

Clinical Trials (1)

Help build intelligence for Lokon Pharma

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to work on cutting-edge oncolytic virus technology, a differentiated modality with significant clinical validation potential
Early-stage company structure allows for meaningful impact on program strategy and direct influence on clinical development decisions
Focused oncology portfolio targeting high-unmet-need indications (melanoma, pancreatic cancer) with first-mover advantage in viral immunotherapy

Watch Out For

No active job openings reported; hiring pipeline appears dormant or undisclosed, limiting near-term employment prospects
All pipeline programs remain in Phase 1/2 with no Phase 3 programs, indicating significant clinical and commercial risk before revenue generation

Generated by Claude from Lokon Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

NCT03225989Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer

Phase 1/2

delolimogene mupadenorepvec

Pancreatic Cancer

Phase 1/2

Clinical Trials (1)

NCT02705196LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer

Phase 1/2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 2 clinical trials

Top TAs: Oncology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

2 pipeline

Marketed

Pipeline